32.jpg)
56.jpg)
A CHAMIGRENIC COMPOUND AS A NAEGLERIA FOWLERI INFECTION TREATMENT.
Patent number:
P202230496
No items found.
The invention discloses the use of a sesquiterpene compound for the treatment or prevention of primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject, preferably of the compound (+)- elatol, and the pharmaceutical composition containing said compound.
Countries:
Spain
Regions:
Canary Islands
Centers:
UNIVERSIDAD DE LA LAGUNA
Other entities:
Universidad Federal de Río de Janeiro
Sectors:
Chemicals
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
High selectivity index Low toxicity values Alternative to existing treatments Treatment of diseases caused by "brain-eating amoeba"
Comments
Other related patents
New & Sustainable Materials
Chemicals
Construction
SELF-CLEANING AND AGGREGATING PRODUCT FOR ROCKS AND OTHER CONSTRUCTION MATERIALS
Chemicals
PROCEDURE FOR THE MANUFACTURE OF IONIC LIQUIDS WITH THE BROMIDE STRUCTURE OF 1, OMEGA-BIS- (3-METHYLIMIDAZOLIUM-1-YL) -ALKANE (OMEGA = 1,2,3,4,5,6) (MACHINE-TRANSLATION BY GOOGLE TRANSLATE, NOT LEGALLY BINDING)
Energy
Chemicals